News

Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma

03/11/2026

Stephanie Holland

Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.

Interim results from the phase 3...

03/11/2026

Oncology

Videos

The Future of Cellular Therapies in Earlier Lines of Multiple Myeloma Treatment

03/06/2026

Natalie Callander, MD

Natalie Callander, MD, shares insights into progress of utilizing cellular therapies in earlier lines of therapy in the multiple myeloma treatment landscape.

Natalie Callander, MD, shares...

03/06/2026

Oncology

FDA Approval

FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma

03/05/2026

Emily Estrada

Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.

Based on results from the phase...

03/05/2026

Oncology

Videos

Addition of Bortezomib to Daratumumab Maintenance Therapy Does Not Improve Progression-Free Survival in Transplant-Ineligible Multiple Myeloma: JCOG1911/ B-DASH Trial

02/27/2026

Tomotaka Suzuki, MD

According to results from a phase 3 trial, adding bortezomib to daratumumab maintenance did not improve PFS in transplant-ineligible patients with newly diagnosed multiple myeloma who responded to daratumumab, melphalan, prednisolone, and...

According to results from a...

02/27/2026

Oncology

Conference Coverage

Ultra-Deep Whole Genome Sequencing of Cell-Free DNA Enhances MRD Detection and Risk Stratification in Multiple Myeloma

02/11/2026

Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.

Dory Abelman, PhD, HBHSc,...

02/11/2026

Oncology

Videos

Teclistamab Plus Daratumumab Demonstrates Significant Survival Benefit for R/R Multiple Myeloma: MajesTEC-3 Trial

01/30/2026

Luciano J. Costa

Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.

Luciano Costa, MD, reported...

01/30/2026

Oncology

Conference Coverage

Evaluating Infection Patterns Among Patients With Multiple Myeloma Receiving BCMA-Targeting CAR T-Cell Therapy

01/26/2026

Bilal Abid, MD, MS, FACP, MRCP, FRCP

Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.

Bilal Abid MD, MS, FACP, MRCP,...

01/26/2026

Oncology

Conference Coverage

Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment

01/22/2026

Ira Zackon, MD

Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.

Ira Zackon, MD, shared results...

01/22/2026

Oncology

Conference Coverage

KTX1001 Monotherapy Shows Clinical Activity and Manageable Safety for R/R Myeloma

01/22/2026

Saad Usmani, MD, MBA, FACP, FASCO

Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.

Saad Usmani, MD, MBA, FACP,...

01/22/2026

Oncology

Conference Coverage

Daratumumab Plus Teclistamab Demonstrates Favorable Safety and Efficacy for Smoldering Multiple Myeloma: REVIVE Study

01/22/2026

C. Ola Landgren, MD, PhD

Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.

Ola Landgren, MD, PhD, shared...

01/22/2026

Oncology

Recent News

FDA Approval

FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma

03/20/2026

Emily Estrada

Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.

Based on results from the SWOG...

03/20/2026

Oncology

News

Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer

03/18/2026

Emily Estrada

According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.

According to a comparative...

03/18/2026

Oncology

News

Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma

03/11/2026

Stephanie Holland

Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...

Interim results from the phase 3...

03/11/2026

Oncology

News

Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma

03/11/2026

Stephanie Holland

Interim results from the phase 3...

03/11/2026

Oncology

News

FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer

03/11/2026

Stephanie Holland

Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.

Based on results from the OSPREY...

03/11/2026

Radiopharmaceutical Education Institute

FDA Alerts

Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial

03/11/2026

Stephanie Holland

Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.

Based on emerging safety data...

03/11/2026

Oncology

News

Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor

03/11/2026

Stephanie Holland

Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.

Updated safety results from the...

03/11/2026

Oncology

News

Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma

03/05/2026

Stephanie Holland

Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.

Results from the phase 3 C-POST...

03/05/2026

Oncology

FDA Approval

FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma

03/05/2026

Emily Estrada

Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.

Based on results from the phase...

03/05/2026

Oncology

News

Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer

03/04/2026

Emily Estrada

Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.

Results from the SWOG S162 study...

03/04/2026

Oncology